Lexeo Therapeutics to Acquire Mantle Therapeutics in Friedreich Ataxia Expansion

Lexeo Therapeutics, Inc. (LXEO) said Tuesday it signed a definitive agreement to acquire privately held clinical-stage company Mantle Therapeutics as part of a series of strategic transactions aimed at expanding its presence in Friedreich ataxia (FA). Terms of the deal were not disclosed. The announcement, dated September 22, 2026, covers multiple transactions, though the company did not provide financial details or a transaction timeline in the initial disclosure. Lexeo is a clinical-stage company developing gene therapies, with Friedreich ataxia among its core programs. Acquiring Mantle adds a private clinical-stage asset to that effort, though the specific pipeline or data involved was not specified.